Fact Source: Financial Supervisory Service DART / 2024-12-18
Disclosure Type: New Investment in Facilities (Amendment)
💡 3-Second Summary
SAMSUNG BIOLOGICS has amended the total investment amount for the construction of Plant 5 at the Songdo Bio Campus, increasing the budget from the initial KRW 1.98T to approximately KRW 2.01T.
📊 1. [Key Disclosure Content & Major Figures Summary]
- Reason for Amendment: Modification of the total investment amount.
- Amendments Made (Data Integrity Verification):
- Investment Amount: Changed from KRW 1,980,100,000,000 to KRW 2,009,800,000,000
- Core Investment Details:
- Investment Type & Target: Construction of a separate facility / Construction of Plant 5 inside the Songdo 2nd Bio Campus
- Final Investment Amount: KRW 2,009,800,000,000 (KRW 2.01T)
- Equity: KRW 8,995,284,255,250 (KRW 9.00T)
- Ratio to Equity: 22.34%
- Investment Period: From March 17, 2023 (Commencement Date) to April 1, 2025 (Expiration Date)
- Facility Capacity: Plant 5 is scheduled to be constructed with a total capacity of 180,000L.
- Key Timeline & Delegation:
- Initial Filing Date: March 17, 2023 / Amendment Filing Date: December 18, 2024
- The investment period’s commencement is fixed to the board resolution date (2023-03-17), while the expiration date is subject to change depending on management environments and internal execution progress. Full authority regarding execution details has been delegated to the Representative Director.
📈 2. [Expert Insight: What This Disclosure Means for Investors]
This amendment filing, submitted on December 18, 2024, primarily updates the investment amount of the ongoing Songdo Plant 5 construction project, ensuring data alignment within the public registry.
The primary fundamental point is the modification of the underlying capital expenditure (CAPEX) metrics. The underlying layout of the factory, including the production capacity (180,000L) and the scheduled expiration date (April 1, 2025), remains unchanged. The updated ledger reflects a budget increase of approximately KRW 29.7B, and data validation shows that the ratio to equity remains matched at 22.34%.
Because the filing does not detail any qualitative causes or specific cost items that triggered this budget adjustment, investors should note that the contract process remains subject to future definitive disclosures. Rather than making definitive assumptions regarding near-term profitability impacts due to increased spending, market participants should monitor whether the facility deployment and asset operations progress according to the designated timeline after April 1, 2025.
📝 Editor’s Comment (by K-STOCK Editor)
SAMSUNG BIOLOGICS has processed an administrative amendment to its active facility investment ledger. According to the document filed on December 18, 2024, the budget for the Songdo Plant 5 construction has been adjusted to roughly KRW 2.01T, marking an increase of about KRW 29.7B from the initially reported framework.
For international investors, this amendment constitutes a mechanical alignment of CAPEX parameters rather than a new immediate operational driver. The significance is restricted to the updated investment amount as recorded in the filing. While budget adjustments are routine during the execution phase of large-scale manufacturing infrastructure, the specific drivers behind this increase are completely absent from this initial text. As indicated in the regulatory notice, the timeline and definitive execution parameters remain subject to future updates, meaning that market participants should monitor subsequent official announcements based strictly on verified data.
📢 Disclaimer and Source Information
Source: This content was newly structured and written based on official data submitted to the Financial Supervisory Service’s Electronic Disclosure System (DART).
Investment Risk Notice: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
